CD86 Expression by Monocytes Influences an Immunomodulatory Profile in Asymptomatic Patients with Chronic Chagas

Bruna F Pinto1, Nayara I Medeiros1,2, Andrea Teixeira-Carvalho2

  • 1Laboratório de Biologia das Interações Celulares, Departamento de Morfologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

Insights

In Chagas disease, higher CD86 expression on monocytes in asymptomatic patients correlates with regulatory T cells. This suggests a potential mechanism for immune regulation and controlling inflammation in indeterminate Chagas disease.

Area of Science:

  • Immunology
  • Infectious Diseases
  • Parasitology

Background:

  • Chagas disease presents an indeterminate (IND) asymptomatic form and a severe cardiac/digestive (CARD) form, with underlying mechanisms poorly understood.
  • Monocyte and lymphocyte interactions, including co-stimulatory molecules CD80/CD86, are crucial for immune responses.
  • Understanding monocyte subset profiles in Chagas disease is vital for elucidating disease progression.

Purpose of the Study:

  • To characterize the functional-phenotypic profile of monocyte subsets in Chagas disease.
  • To investigate the expression of co-stimulatory molecules (CD80, CD86) and other immune markers in IND and CARD patients.
  • To explore the relationship between monocyte subsets and T lymphocyte activation in Chagas disease.

Main Methods:

  • Flow cytometry was used to analyze monocyte subsets from IND, CARD, and non-infected (NI) individuals.
  • Cells were stimulated *in vitro* with *Trypanosoma cruzi* antigens.
  • Expression of CD80, CD86, TLR-2, TLR-4, TLR-9, HLA-DR, IL-10, IL-12, CTLA-4, and CD28 was assessed.

Main Results:

  • Higher CD86 expression was observed on monocyte subsets in IND patients compared to NI individuals.
  • IND patients showed a higher frequency of CD4+CTLA-4+ T lymphocytes after *T. cruzi* stimulation.
  • Associations were found between CD80/CD28 and CD86/CTLA-4, with a high frequency of regulatory T (Treg) cells in IND patients.

Conclusions:

  • CD86 may play a role in immunoregulation in asymptomatic Chagas disease through association with CTLA-4.
  • The CD86-CTLA-4 interaction could influence Treg cell activation, potentially controlling inflammation and tissue damage.
  • This study reveals novel insights into monocyte subset function in Chagas disease pathogenesis.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
558
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.6K
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
766
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.9K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.2K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
683